TRT: The Testosterone Replacement Therapy Guide

What TRT is and what it is for

TRT supplies exogenous testosterone to replace — or compensate for — a failing endogenous production. Medically, it is the standard treatment for confirmed male hypogonadism: a biologically low testosterone level combined with clinical symptoms. The goal is not to push to the top of the range, and not to add muscle — it is to restore a hormonal balance compatible with health, libido, body composition, mood and energy. US TRT clinics (Defy Medical, Marek Health, Hone Health, Maximus) and compounding pharmacies (Empower Pharmacy) work from the same framework, even when their delivery models differ.

Two broad categories of hypogonadism are treated with TRT. Primary hypogonadism is a direct testicular problem — genetic conditions (Klinefelter), trauma, post-infectious damage, chemotherapy — where LH and FSH are elevated but the testes do not respond. Secondary hypogonadism sits upstream, at the hypothalamic-pituitary level — pituitary tumors, head trauma, certain medications — where LH and FSH are low or inappropriate. A full hormonal workup (total T, free T, SHBG, LH, FSH, prolactin) draws the distinction, as detailed in interpreting hormonal markers.

Who actually qualifies for TRT

A hypogonadism diagnosis rests on two pieces fitting together: a confirmed low total testosterone (ideally two morning fasting draws at least a week apart) AND compatible clinical symptoms. One without the other is not enough. An isolated low number in an asymptomatic man warrants follow-up, not necessarily treatment. Symptoms without a low number point somewhere else — sleep, depression, deconditioning, medication side effects ^[1].

Reference ranges in practice

• Physiological range for total testosterone in adult men: roughly 300 to 1000 ng/dL (10 to 35 nmol/L). Exact cut-offs vary by lab and by guideline body (AUA, Endocrine Society).
• Common low threshold: < 300 ng/dL (about < 10 nmol/L) on two morning draws — the level at which TRT starts to get seriously considered if symptoms are present ^{[1] [2]}.
• Free T and SHBG round out the picture: a total in range with a low free T (very high SHBG) can still justify treatment.
• LH and FSH tell you the cause: elevated → primary; low or inappropriate → secondary.

Main indications

• Confirmed primary hypogonadism (Klinefelter, anorchia, post-chemo damage).
• Confirmed secondary hypogonadism of hypothalamic-pituitary origin.
• Persistent post-cycle hypogonadism after several failed PCT attempts — see the PCT protocol guide.
• Late-onset hypogonadism in older men, with symptoms and biochemical confirmation — a more debated indication, evaluated case by case.

Esters and injection frequency: the protocol baseline

Modern injectable TRT relies almost exclusively on a long testosterone ester: testosterone cypionate (test cyp) in US TRT practice, testosterone enanthate in UK and EU practice. The two are functionally interchangeable for TRT — enanthate (half-life ~4.5 days) and cypionate (~5 days) both give a stable kinetic profile, without aggressive peaks or deep troughs between doses.

Dose and frequency

To map ester decay between injections and dial in frequency, the half-life calculator is a useful reference. Rule of thumb: if your trough readings (drawn just before the next injection) show a steep drop in T or estradiol, split the dose more often. The subQ vs IM TRT debate is largely settled in favor of either at physiological doses — patient preference and skin reaction drive the choice.

Alternatives to injection

• Transdermal gels (AndroGel, Testim, Fortesta): daily application, smoother serum levels but higher cost, risk of skin transfer to a child or partner, and variable absorption.
• Patches (Androderm): less common in US TRT clinics today, frequent skin irritation.
• Subcutaneous pellets (Testopel): inserted every 3 to 6 months, no daily routine, but dose is locked in for the period and removal is invasive.
• Oral testosterone undecanoate (Jatenzo, Kyzatrex): FDA-approved, twice-daily dosing, expensive, must be taken with food.
• Nasal gel (Natesto): interesting fertility profile (preserves LH/FSH better than other delivery modes), but three-times-daily application is a major adherence hurdle.

HCG and fertility preservation on TRT

Exogenous testosterone on TRT shuts down LH and FSH secretion — this is mechanical and visible on any post-start bloodwork. FSH drives spermatogenesis, so its loss collapses sperm production in the vast majority of men. For a young patient, or anyone who is not done with family planning, this is a major point to address before the first injection, not after.

Adding HCG alongside the testosterone (typically 250 to 500 IU two to three times per week) mimics LH and keeps the testes active, including spermatogenesis ^[7]. Most men maintain normal testicular volume, retain enough sperm production for functional fertility, and report a better subjective feel on the protocol. For the protocols in detail and alternatives, see TRT and fertility and HCG on cycle and PCT.

Estradiol and aromatase inhibitors: restraint is the rule

Part of the testosterone aromatizes to estradiol — that is physiological and necessary. At TRT doses (100 to 200 mg/week), estradiol rises modestly and usually stays in or just above the normal male range. Estradiol contributes to libido, bone health, cognition and overall well-being: a crashed estradiol in a man is just as harmful as one that runs too high.

The classic 'gray TRT' (self-administered) mistake is to prescribe an aromatase inhibitor systematically 'for safety'. In supervised practice, an AI gets introduced only with a measured out-of-range estradiol AND associated clinical signs (early gyno, marked water retention, estrogen-driven irritability). On a sensitive (E2 sensitive) assay — the only valid measure in men — many TRT patients never need an AI. When one is introduced, it is at the minimum dose and titrated against lab values. See aromatase inhibitors on cycle for the deep dive.

Lifelong monitoring: labs, markers, adjustments

TRT is not a 'set and forget' prescription. It demands a recurring lab schedule for life — to titrate the dose, watch for side effects, and catch complications early. The AnaProtoKol blood-work feature lets you archive, date and trend these markers across years, which is exactly what your endocrinologist needs at the next visit.

Typical TRT monitoring schedule

Key markers to watch

• Hematocrit: TRT increases red blood cell production. Above 52 to 54%, thrombotic risk climbs. Management: blood donation, dose reduction, more frequent splitting. See hematocrit and steroids.
• PSA and prostate: TRT does not cause prostate cancer, but it can reveal a pre-existing one or accelerate benign hyperplasia. Annual surveillance after 40, tighter with family history ^[5].
• Lipid panel: HDL can drift. Trend it. See cholesterol on cycle.
• Blood pressure: sodium retention can push BP up. Home cuff, regular readings ^[3]. See heart health on cycle.
• Sleep apnea: TRT can unmask or worsen apnea. Loud snoring, daytime fatigue or morning headaches warrant a sleep study.

For the broader monitoring framework, see the pillar blood work on cycle and the timing in blood test schedule on cycle.

Medical TRT vs gray TRT: the difference is real

A portion of TRT users self-administer without a formal diagnosis — usually after a cycle whose HPTA never recovered, or from empirical convenience. This 'gray TRT' is not equivalent to physician-supervised TRT. The differences are structural, not cosmetic. US forums (r/Testosterone, r/TRT, r/Hone, Excelmale, MESO-Rx TRT section) document both worlds, and the failure modes of the gray version are repeated week after week.

Expected effects, side effects, risks

Expected effects at physiological dose

• Improved libido and erectile function (often noticeable within 4 to 8 weeks) ^[4].
• Gradual return of energy, motivation, sometimes mood ^[4].
• Modest but real recovery of strength and lean mass — without transforming the physique ^[4].
• Better bone mineral density over the long term ^[5].
• Gradual decline in abdominal fat.

Possible side effects

• Erythrocytosis (high hematocrit): the most common long-term effect ^[6]. Manage with blood donation, lower dose, or more frequent splitting. See hematocrit and steroids.
• Acne, oily skin, accelerated androgenic hair loss in predisposed individuals. See hair loss on steroids.
• Suppression of spermatogenesis — manageable with HCG alongside if fertility matters.
• Testicular atrophy — reduced with HCG; without HCG, testicular volume drops progressively.
• Moderate fluid retention, usually early in the protocol and transient.
• Mood swings, possible irritability when estradiol is mis-tuned.

Major contraindications

• Active prostate or breast cancer.
• Uncorrected high hematocrit at baseline.
• Severe uncompensated heart failure.
• Severe untreated sleep apnea.
• Immediate fatherhood plans without HCG co-administration or a clomiphene-style alternative.

For the full picture of androgen side effects (relevant for TRT and cycles at very different intensities), see the pillar steroid side effects guide.

Coming off TRT: possible but slow

A long-running TRT has a durably suppressed HPTA. That does not mean stopping is impossible, but it is rarely easy and always slow. Three main scenarios:

• Recent TRT (< 1 year) in a young man: a medically supervised restart protocol (HCG plus a SERM, sometimes recombinant gonadotropins) can reignite the axis. Higher success rate, but no guarantee.
• Long-term TRT: restart is more uncertain. A fraction of patients recover acceptable endogenous production; others stay dependent on some form of treatment for life.
• Primary hypogonadism (genetic or anatomical): there is no recovery to expect — the treatment is and will remain lifelong.

In every case, stopping or attempting to stop is done under medical supervision, never abruptly. Coming off TRT to switch to a performance cycle is a poorly conceived plan documented many times over — see TRT vs steroid cycle.

Frequently asked questions